Evaluation of five screening tests licensed in Argentina for detection of hepatitis C virus antibodies

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue 3, 2005, Pages 303-307

  Ré, Viviana ^a   Gallego, Sandra ^a   Treviño, Elena ^b   Barbás, Gabriela ^a   Domínguez, Claudia ^b   Elbarcha, Osvaldo ^c   Bepre, Héctor ^b   Contigiani, Marta ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

Author keywords

HCV screening test; Hepatitis C virus (HCV); Sensitivity

Indexed keywords

VIRUS ANTIBODY;

AGGLUTINATION TEST; ANTIBODY DETECTION; ARGENTINA; ARTICLE; ASSAY; COMPARATIVE STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROCONVERSION;

HEPATITIS C VIRUS; MUREX;

EID: 21044448107     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762005000300016     Document Type: Article

References (30)

1. Aach R, Stevens C, Hollinger H, Mosley J, Peterson D, Tylor P, Johnson R, Barbosa L, Nemo G 1991. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second- generation assays. New Engl J Med 325: 1325-1329.
2. Busch MP, Stramer SL, Kleinman SH. 1997 Evolving applications of nucleic acid amplification assays for prevention of virus transmission by blood components and derivatives. In G Garraty, Applications of Molecular Biology to Blood Transfusion Medicine, American Association of Blood Banks, Bethesda, p. 123-177.
3. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C 2001. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: analysis of the literature. J Viral Hep 8: 87-95.
4. Courouce AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, Simon N 2000. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion 40: 1198-1202.
5. Delle Monache M, Micelli M, Santolamazza M, Mannella E, Mercurio G, Di Lorenzo A, Bacosi M, Gerardi R, Berardo C, Bruno G, Russo F, Miglioresi L, Ricci GL 1999. Elevated alanine aminotranferase in blood donors: role of different factors and multiple viral infections. J Int Med Res 27: 134-142.
6. Donahue J, Muñoz A, Ness P, Brown Jr DE, Yawn DH, McAllister Jr HA, Reitz BA, Nelson KE 1992. The declining risk of posttransfusion hepatitis C virus infection. N Engl J Med 327: 369-373.
7. Glynn SA, Kleinman SH, Schreiber GB, Busch MP, Wright DJ, Smith JW, Nass CC, Williams AE 2000. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 284: 229-235.
8. Holland P 2000. Old and new tests. Where will it end? Vox Sang 78: 67-70.
9. Icardi G, Ansaldi F, Bruzzone BM, Durando P, Lee S, de Luigi C, Crovari P 2001. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol 39: 3110-3114.
10. Jackson BR, Busch MP, Stramer SL, AuBuchon JP 2003. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43: 721-729.
11. Janot C, Courucé AM, Bourdart D, Cotte C, Elghouzzi MH, Jullien AM, Lemaire JM, Maisonneuve P, Maniez-Montreuil M, Mattlinger B 1992. Analytical study of Abbot and Ortho tests for screening and confirmation of ariti-HCV antibodies. Le Group de Travail Hépatites Virales de la Societé Francaise de Transfusion Sanguine. Rev Fr Transf Hemobiol 35: 171-182.
12. Kleinman S, Alter H, Busch M, Holland P, Tegtmeier G, Nelles M, Lee S, Page E, Wilber J, Polito A 1992. Increased detection of hepatitis C virus (HCV) infected blood donors by multiple antigens HCV enzyme immunoassay. Transfusion 32: 806-813
13. Kleiman S, Busch M, Korelitz J, Schereiber G 1997. The incidence/window period model and its use to assess the risk of transfusion-transmitted HIV and HCV viral infection. Transfus Med Rev 11: 155-172.
14. Koemer K, Cardoso M, Dengler T, Kerowgan M, Kubanek B 1998. Estimated risk of transmission of hepatitis C virus by blood transfusion. Vox Sang 78: 213-216.
15. Leon P, Lopez J, Elola C, Domingo CJ, Echevarria JM 1994. Are synthetics peptides sensitive enough for screening anti hepatitis C virus at blood banks? Vox Sang 67: 83-84.
16. Lozano M, Cid J, BediniJL, Mazzara R, Jiménez N, Mas E, Ballesta A, Ordinas A 1998. Study of serum alanine-aminotransferase levels in blood donors in Spain. Haematologica 83: 237-239.
17. Lunel F, Rosenheim M, Duneton P 1996. Proposition pour une stratégie d'évaluation et d'utilisation des tests de déspistage de l'hépatite C. Transf Clin Biol 5: 279-288.
18. Majid AM, Gretch DR 2002. Current and future hepatitis C virus diagnostic testing: problems and advancements. Microbes and Infection 4: 1227-1236.
19. Mendes de Oliveira J, Rispeter K, Viazov S, Saback F, Roggendorf M, Yoshida C 2001. Differences in HCV antibody patterns in haemodialysis patients infected with the same virus isolate. J Med Virol 63: 265-270.
20. Morishima CG 1999. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy. Clin Liver Dis 3: 717-740.
21. Muerhoff AS, Jiang L, Shah DO, Gutierrez RA, Patel J, Garolis C, Kyrk CR, Leckie G, Frank A, Stewart JL, Dawson GJ 2002. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion 42: 349-356.
22. Paul-Ehrlich-Institut, Bundesamt für sera und Impfstoffe 1998. Results of the phased plan to reduce the infection risk in hepatitis B, C and HIV in recipients of packed red cell transfusions (German). Bundesanzeinger 53: 3835-3836.
23. Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM 2002. Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 42: 980-988.
24. Schmuñis G, Zicker F, Segura E, del Pozo A 2000. Transfusion-transmitted infectious diseases in Argentina, 1995 through 1997. Transfusion 40: 1048-1053.
25. Schreiber G, Busch M, Kleinman S, Korelitz J 1996. The risk of transfusion-transmitted viral infections. N Engl J Med 334: 1685-1690.
26. Stramer SL, Caglioti S, Smong DM 2000. NAT of United States and Canadian blood supply. Transfusion 40: 1165-1168.
27. Stramer SL, Porter RA, Brodsky JP 1998. Sensitivity of HIV and HCV RNA detection by pooled genome amplification testing (GAT). Transfusion 38: 70.
28. Van der Poel CL, Cuypers HT, Reesink HW 1994. Hepatitis C virus, six years on. Lancet 344: 1475-1479.
29. Van der Poel C, Cuypers H, Reesink H, Choo Q, Kuo G, Hon J, Quon S, Polito A, Verstrater J, Van der Wouw J 1991. Risk factors in hepatitis C virus-infected blood donors. Transfusion 31: 777-779.
30. Weber B, Rabenau H, Berger A, Scheuermann EH, Staszewski S, Kreuz W, Scharrer I, Schoeppe W, Doerr HW 1995. Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups, Frankfurt a. M., Germany. Zentralbl Bateriol 282: 102-112.